|
|
 |
 |
| home / news & events |
|
6/23/2009
Lophius BioSciences fulfils central milestone
This start-up company located in BioPark Regensburg has reached an important milestone in the development of new test procedures in the diagnosis of infectious diseases. With the aid of so-called proprietary T-cell technology, this company has been successful with a novel and highly innovative application.
Lophius Biosciences GmbH is a spin-off from the University Clinic in Regensburg and financed by the High-Tech Gründerfonds and Bayern Kapital. The young biotech company develops so-called T-cell kits to secure diagnosis of active infectious diseases requiring treatment. T-cells are an important group of the white blood cells and are part of the body’s defence system. They are formed in the bone marrow and have the task of recognising and destroying sick cells and foreign infectious agents. The T-cell kits from Lophius can however also be used for the early recognition of autoimmune disease and prediction of transplantation-related complications. Furthermore the Regensburg company offers services for the quality control and assessment of the efficacy and safety of biologically active substances. With reverse T-cell technology (RTT) and urea processes, Lophius has developed two innovative, proprietary platform technologies. The milestone of patient probes for RTT has also been produced. This technique forms the basis for the development of Tcell kits for the determination of active tuberculosis and for the recognition of multiple sclerosis and type 1 diabetes in the early stages of the onset of disease.
Source:
Transcatheter Technologies GmbH
Lophius BioSciences GmbH
BioPark Regensburg GmbH
|
|
| |
|
|
|
|
 |
 |
 |
Assistance for U.S. Investors
|
|
|
|
